Ieq Capital LLC Buys New Stake in Twist Bioscience Corporation $TWST

Ieq Capital LLC purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, HoldingsChannel.com reports. The fund purchased 51,109 shares of the company’s stock, valued at approximately $5,258,000.

Several other hedge funds have also bought and sold shares of TWST. GAMMA Investing LLC lifted its position in shares of Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares in the last quarter. Stifel Financial Corp grew its holdings in Twist Bioscience by 3.6% during the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after buying an additional 271 shares in the last quarter. D.A. Davidson & CO. increased its stake in Twist Bioscience by 1.2% in the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after acquiring an additional 305 shares during the last quarter. CWM LLC increased its stake in Twist Bioscience by 9.4% in the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after acquiring an additional 407 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after acquiring an additional 442 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TWST. Leerink Partners set a $110.00 target price on Twist Bioscience in a research report on Thursday, July 16th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Guggenheim upped their price target on shares of Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Finally, Barclays lifted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $98.30.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $145.59 on Monday. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -65.58 and a beta of 2.14. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $145.93. The firm’s 50-day moving average is $100.69 and its 200 day moving average is $70.50. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period in the previous year, the business earned $0.33 EPS. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. Research analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 113,318 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the sale, the chief executive officer owned 818,938 shares in the company, valued at approximately $102,498,280.08. The trade was a 12.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares of the company’s stock, valued at $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 151,529 shares of company stock valued at $17,708,772 in the last three months. 3.08% of the stock is owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.